Let's Know Things cover art

Let's Know Things

Let's Know Things

By: Colin Wright
Listen for free

A calm, non-shouty, non-polemical, weekly news analysis podcast for folks of all stripes and leanings who want to know more about what's happening in the world around them. Hosted by analytic journalist Colin Wright since 2016.

letsknowthings.substack.comColin Wright Politics & Government
Episodes
  • Balcony Solar

    Balcony Solar
    Jun 23 2026
    This week we talk about plug-in power, renewables, and Germany.We also discuss inverters, solar arrays, and microgrids.Recommended Book: Consider This by Chuck PalahnuikTranscriptMost climate scientists and knowledgable folks in adjacent fields will tell you that, as a species, we’re way behind where we need to be if we’re going to avoid a whole lot of negative consequences caused by global climate change.We’ve blazed past a bunch of tipping points already, and while the worst-case scenarios we were worried about a decade ago are no longer likely because of the energy-generation and related changes we’ve made globally, since then, the damage caused up to this point is already doing some pretty bad things to our water cycle and other temperature-regulating systems, and that’s looking like it will get even worse over the next several decades—even if worse no longer means cataclysmic in the sense of ending all life on the planet.That said, even noting that progress has been a lot slower than most experts would prefer, progress is happening in regards to the deployment of renewable energy sources, and in the replacement and retirement of dirty, carbon- and methane-spewing sources, like coal, petroleum, and gas.As of 2026, the global share of total electricity generation, so all electricity produced by all sources for all purposes, is about 33.8% for renewables, marking the first time renewables have been used to produce more than a third of the total electricity produced, globally; that also means renewables have surpassed coal for electricity generation for the first time.While hydro and wind continue to contribute to the growth of renewables deployment and electricity generation, solar power is by far the biggest growth area for renewables right now, and solar, alone, covers 75% of total electricity demand growth in 2025—which means as countries around the world deploy more electricity generation assets to account for electricity demand growth, three-quarters of that demand is being met by solar. And this is notable because typically that kind of demand, the majority of which arises in huge, rapidly scaling countries like China and India, has up till recently been met by the dirtiest of energy production sources, coal.There’s also been a .02% reduction in fossil fuel generation, year-on-year, which is a very small number, but that level of production is massive, and there are a lot of subsidies and other mechanisms that keep fossil fuels flourishing around the world, so every little sliver of fossil fuel energy production reduction is still a pretty significant thing.Many of these renewables-related wins, in recent years, have been attributable to the large-scale installation of solar facilities, backed by massive, utility-scale battery backups, primarily in China.China is by far the largest producer of solar panels and related technologies—Chinese companies produce somewhere between 80-90% of all the key components and perform the same portion of all key manufacturing stages for the global supply chain, while also controlling the vast majority of resources necessary to manufacture solar panels. And it has been on a tear over the past decade or so, installing just a silly amount of solar infrastructure. Which is good, because China is also seeing a lot of growth in energy demand, so if they weren’t deploying that much solar, they would likely be deploying that much coal infrastructure, instead.That said, while huge solar arrays are important to renewables growth, there’s also been a recent boom in smaller-scale solar energy deployment in recent years, especially but not exclusively across Europe. And that’s what I’d like to talk about today: the emergence of so-called ‘balcony solar,’ and what it might mean for the further expansion of solar’s footprint around the world.—In 2025, Utah, which is a deeply Conservative, Republican state, became the first US state to pass a bill that makes it easier to legally install plug-in solar panel systems.As of mid-2026, about 30 states have followed suit, and even more are considering it, laws allowing for the installation of such solar technologies winding their way through legislative bodies on the back of the popularity and seeming no-downsides nature of this tech product category.Plug-in solar, also sometimes called balcony solar or garden solar, is currently most popular in Germany, which is the biggest market for this product right now, with about four million such systems installed as of 2025.To understand the popularity of this type of solar installation, it’s useful to understand that conventional solar installations have typically required a decent amount of electrical surgery to install. They’ve usually involved a large number of panels operating as an array, and that array has produced quite a lot of electricity that then has to be funneled as a direct current either back into the local grid using what amounts to ...
    Show More Show Less
    14 mins
  • Cholesterol Therapies

    Cholesterol Therapies
    Jun 16 2026
    This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what’s called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it’s found throughout their bodily tissues, as well, and again, it’s vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it’s bound to what’s called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one’s overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I’d like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that’s how far out they’re retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it’s useful to know some health stats. And I’m going to focus on the US here, as that’s where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn’t come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come ...
    Show More Show Less
    14 mins
  • SpaceX IPO

    SpaceX IPO
    Jun 9 2026
    This week we talk about initial public offerings, Anthropic, and investment flywheels.We also discuss AI, financial entanglements, and backstops.Recommended Book: Superconvergence by Jamie MetzlTranscriptAn initial public offering, or IPO, is what happens when a private company goes public and starts selling shares of itself, occasionally to just institutional investors like banks and sovereign wealth funds, but usually also to retail investors, which means normal people who buy stocks as part of their investment strategy.Often private companies go this route, go public, because it’s one of the primary ways of gleaning new, oftentimes large inflows of money, and that money can then be used for investments in assets for the company, but it also allows employees who have shares in the company as part of their compensation to cash out, to get paid possibly a huge bonus for all their efforts, and it’s often a means by which executives garner huge paydays for themselves, because they can now sell their accumulated shares, or borrow against them, or because they have something in their contract that says they get x amount of bonus money or new shares if they take the company public, or achieve a certain valuation goal—and going public is a good way to do that.This is also one of the primary ways investors in a company, whether that’s a bunch of smaller seed investors or big-name venture capitalists, to get their money back; the 10 or 100x-ing of their investment, getting ten or 100-times the money they put into the company, generally happens through an IPO, because it can balloon the valuation of that company, and it gives them a more conventional and reliable way of getting money back for their shares: they can just sell those shares on the open market.So an IPO allows a private company to make shares of itself available to others, on scale. And the ‘initial’ part of initial public offering points at the early days of the process, during which the baseline price of a share of stock is established.A fairly arcane and complex process has emerged around this, and it’s an entire industry at this point, with some institutions specializing in taking companies public, helping them get as high an initial price on that stock as possible. They also help them leap all sorts of regulatory hurdles set by the Securities and Exchange Commission, if they’re going public on a US exchange, at least, other bodies handle such things in other countries, and these going-public entities, called underwriters, which are usually investment banks, also typically have their own stake in the matter, earning compensation through a fee called a ‘gross spread,’ which is the difference between a discounted rate on the stock and what the stock is sold for on the open market on that first day it’s available.What I’d like to talk about today is a wave of very closely watched unusual, impending IPOs that are coming later this year, and one of them in particular that looks to be even more unusual than the rest.—SpaceX, OpenAI, and Anthropic are three of the largest companies in human history; on paper, at least.And that’s an important caveat. Market valuation for private companies is generally determined by how much investors are willing to spend on a percentage ownership of the company. So if you start a lemonade stand and I offer to buy 1/10th of that lemonade stand from you for $100, that implies, using this logic, that your lemonade stand has a valuation of $1000; 10 times that $100 that I offered to pay you.Such valuations are also informed by independent analyses from outside experts and institutions. SpaceX, for instance, pre-IPO, is estimated to be worth somewhere between $780 billion and nearly $2 trillion, depending on who you listen to, based on their assets, their potential future earnings, and any advantages they might have in the markets in which they operate.AI company Anthropic is estimated to be worth something like $965 billion, based on a May 2026 series H funding round, through which it raised $65 billion; based on that funding round, the calculations were done, and just shy of a trillion dollars is what the math says the company is worth, though some outside analyses say it’s worth a bit less than that, while others suggest it’s maybe closer to $1.4 trillion.OpenAI, a direct competitor of Anthropic, is valued at about $100 billion less than Anthropic based on its most recent $122 billion funding round, but again, analyses put the company’s actual value, what people and investors would pay for it on the open market, all over the place.Each of these companies have different variables acting upon them heading into a period in which it’s expected that all three will IPO.OpenAI kicked off the current AI race, for instance, but it’s burning money at an incredible rate, and has yet to make a profit, losing billions per year, and will probably continue to lose billions each year for a while ...
    Show More Show Less
    19 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.